Lineage Cell TherapeuticsLCTX +1.23%78 PB Ratio is 5.72 as of Jun. 26, 2026, which is 114% above its 10-year median of 2.67. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.33 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,232 Biotechnology companies, Lineage Cell Therapeutics ranks worse than 74.43% on this metric.
The historical rank and industry rank for Lineage Cell Therapeutics's PB Ratio or its related term are showing as below:
LCTX'
s PB Ratio Range Over the Past 10 Years
Min: 0.64 Med: 2.67 Max: 20
Current: 5.61
During the past 13 years, Lineage Cell Therapeutics's highest PB Ratio was 20.00. The lowest was 0.64. And the median was 2.67.
LCTX's PB Ratio is ranked worse than 74.43% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs LCTX: 5.61
During the past 12 months, Lineage Cell Therapeutics's average Book Value Per Share Growth Rate was -37.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -24.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -10.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Lineage Cell Therapeutics was 63.80% per year. The lowest was -167.40% per year. And the median was -10.30% per year.
Back to Basics: PB Ratio
Lineage Cell Therapeutics (AMEX:LCTX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lineage Cell Therapeutics PB Ratio Related Terms
Lineage Cell Therapeutics PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lineage Cell Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lineage Cell Therapeutics (LCTX) has a PB Ratio of 5.72 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lineage Cell Therapeutics and its competitors. This is 114% above median its historical median of 2.67. Over the past decade, Lineage Cell Therapeutics' PB Ratio has ranged from 0.64 to 20.00. According to the industry distribution chart, Lineage Cell Therapeutics ranks #917 out of 1232 companies in the Biotechnology industry, placing it in the top 74.4%.
Is Lineage Cell Therapeutics' PB Ratio too high?
Lineage Cell Therapeutics' current PB Ratio of 5.72 is 114% above median its 10-year median of 2.67. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 20.00. The Biotechnology industry median PB Ratio is 2.80. Lineage Cell Therapeutics' value of 5.72 is 104.3% above this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #917 out of 1232 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' PB Ratio compare to FATE and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #917 out of 1232 companies for PB Ratio. This places Lineage Cell Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Lineage Cell Therapeutics' value of 5.72 is 104.3% above this benchmark. Historically, Lineage Cell Therapeutics' own PB Ratio has ranged from 0.64 to 20.00 over the past decade. While the company's 10-year median is 2.67 vs. the industry median of 2.80, Lineage Cell Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current PB Ratio of 5.72 is 104.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current PB Ratio is 5.72, which is 114% above median its own 10-year median of 2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Fairly Valued. The stock's GF Value™ is $1.33, compared to a current price of $1.24 — trading 7.1% below its estimated fair value. The current PB Ratio is 5.72, which is 114% above median its 10-year median of 2.67 and 104.3% above the Biotechnology industry median of 2.80. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current PB Ratio is 5.72 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.24 is trading 7.1% below its estimated GF Value™ of $1.33.
GuruFocus considers Lineage Cell Therapeutics to be Fairly Valued.
Key valuation signals for LCTX:
PB Ratio: 5.72 (114% above median its 10-year median of 2.67)
GF Value™: $1.33 vs. price of $1.24 (7.1% below fair value)
Industry Position: 104.3% above the Biotechnology median (#917 of 1232)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
